VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Phase 1 Withdrawn ViiV Healthcare

RandomizedSequentialDouble-blindTreatment

This study will assess safety, tolerability and pharmacokinetic (PK) of VH3739937 in healthy participants.

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran etexilate	Unknown	—	Oral
Subject	Digoxin	Other / unclassified	—	Oral
Subject	Midazolam	Small molecule	—	Oral
Subject	Rosuvastatin	Small molecule	—	Oral
Subject	ZEGRUVIRIMAT	Small molecule	100 mg	Oral
Subject	ZEGRUVIRIMAT	Small molecule	500 mg	Oral